全文获取类型
收费全文 | 290785篇 |
免费 | 11923篇 |
国内免费 | 8157篇 |
专业分类
耳鼻咽喉 | 2367篇 |
儿科学 | 7785篇 |
妇产科学 | 3924篇 |
基础医学 | 28332篇 |
口腔科学 | 3420篇 |
临床医学 | 25391篇 |
内科学 | 45286篇 |
皮肤病学 | 1897篇 |
神经病学 | 21317篇 |
特种医学 | 13901篇 |
外国民族医学 | 28篇 |
外科学 | 42273篇 |
综合类 | 26830篇 |
现状与发展 | 23篇 |
一般理论 | 5篇 |
预防医学 | 27522篇 |
眼科学 | 5217篇 |
药学 | 21758篇 |
97篇 | |
中国医学 | 8667篇 |
肿瘤学 | 24825篇 |
出版年
2024年 | 373篇 |
2023年 | 1453篇 |
2022年 | 3826篇 |
2021年 | 5034篇 |
2020年 | 4050篇 |
2019年 | 3401篇 |
2018年 | 25137篇 |
2017年 | 20703篇 |
2016年 | 22734篇 |
2015年 | 6207篇 |
2014年 | 7308篇 |
2013年 | 7570篇 |
2012年 | 16281篇 |
2011年 | 30674篇 |
2010年 | 26158篇 |
2009年 | 17618篇 |
2008年 | 26335篇 |
2007年 | 28705篇 |
2006年 | 7237篇 |
2005年 | 7847篇 |
2004年 | 8463篇 |
2003年 | 9938篇 |
2002年 | 7465篇 |
2001年 | 4123篇 |
2000年 | 2912篇 |
1999年 | 1824篇 |
1998年 | 1223篇 |
1997年 | 1185篇 |
1996年 | 762篇 |
1995年 | 673篇 |
1994年 | 582篇 |
1993年 | 343篇 |
1992年 | 338篇 |
1991年 | 362篇 |
1990年 | 342篇 |
1989年 | 274篇 |
1988年 | 205篇 |
1987年 | 180篇 |
1986年 | 128篇 |
1985年 | 128篇 |
1984年 | 57篇 |
1983年 | 58篇 |
1982年 | 50篇 |
1980年 | 57篇 |
1974年 | 27篇 |
1938年 | 60篇 |
1937年 | 25篇 |
1934年 | 30篇 |
1932年 | 56篇 |
1930年 | 46篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
目的:观察喉罩全麻下行颈动脉狭窄的造影诊断及介入治疗术的临床效果。方法:择期DSA下颈动脉狭窄患者23例,年龄42-78岁,无明显肺部疾患及喉罩禁忌症患者,异丙酚(Pmpofol)泵入静脉全麻下插入喉罩完成手术,观察其不同时段的BP(MAP)、SpO2、HR、ECG(ST-Ⅱ)。结果:各时段的BP(MAP)、Sp02、HR、ECG(ST-Ⅱ)比较无显著性差异。结论:喉罩全麻在行颈动脉狭窄的造影诊断及介入治疗术的临床效果是肯定的。喉罩全麻颈动脉狭窄造影介入治疗 相似文献
53.
Statutory reimbursement agencies as well as private insurers throughout member states of the Organization for Economic Cooperation and Development (OECD) reimburse the cost of medicines on the basis of criteria that include robust clinical evidence, budget impact analysis, and incremental cost effectiveness. The Centers for Medicare and Medicaid Services (CMS) in the US are no exception to this rule and are, in principle, seeking to maximize benefit for their Medicare enrollees, whilst ensuring reasonable drug outlays for the small number of drugs that they reimburse. This paper provides a retrospective analysis of the way two functionally equivalent drugs are treated for reimbursement purposes by the CMS; the period under consideration was 2001–3. The two drugs, epoetin-α and darbepoetin-α, are used for the treatment of anemia in renal failure and in patients receiving chemotherapy. By reviewing the publicly available pharmacological and clinical data of epoetin-α and darbepoetin-α, the paper confirms the two drugs’ functional equivalence, despite their structural differences. The implications of dose conversion ratios and costs to Medicare are subsequently explored. It is argued that the issue of dose equivalence between epoetin-α and darbepoetin-α has significant implications for patients, practitioners, and payors. A payor’s perspective is adopted in this respect, whereby clinical evidence and pricing data are used simultaneously. Based on the clinical evidence, a dose conversion ratio for epoetin-α:darbepoetin-α is established, which achieves a comparable clinical effect for the two drugs and this is set to be <254IU:1μg. The incremental costs to Medicare are calculated subsequently. The Average Wholesale Price and the Outpatient Prospective Payment System rule that Medicare uses to reimburse providers are used and suggest that treatment of cancer patients with chemotherapy-related anemia with epoetin-α would save Medicare an estimated $US600 million each year. Patients would also benefit significantly in terms of lower co-payments for epoetin-α. The evidence is supportive of the decision made by the CMS to reimburse the two drugs at the rate reflecting the achievement of comparable clinical effects and therefore reducing the pass-through payments for darbepoetin-α to zero for the 2002–3 fiscal year. 相似文献
54.
55.
他汀类药物对心血管的保护作用 总被引:6,自引:0,他引:6
他汀类药物(statins)被研制出来的最初目的是降低血脂,但是现在发现它不仅具有降低血脂的作用,还具有很多其他的作用包括改善内皮细胞功能的紊乱,提高内皮源性一氧化氮合成酶的生物活性,抑制血管平滑肌细胞的增殖,抗氧化作用,抗炎作用,降低血压,逆转心血管系统的重构。充分理解statins的多效性作用及机制有利于它更好的在临床中被应用于心血管系统的预防和治疗。 相似文献
56.
57.
Chang Y Jung Hyo S Choi Jin S Ju Hyo S Park Tae G Kwon Yong C Bae Dong K Ahn 《The journal of pain》2006,7(10):747-756
The present study investigated the role of central metabotropic glutamate receptors (mGluRs) in interleukin-1beta (IL-1beta)-induced mechanical allodynia and mirror-image mechanical allodynia in the orofacial area. Experiments were carried out on male Sprague-Dawley rats weighing 230 to 280 g. After administration of 0.01, 0.1, 1, or 10 pg of IL-1beta into a subcutaneous area of the vibrissa pad, we examined the withdrawal behavioral responses produced by 10 successive trials of an air-puff ramp pressure applied ipsilaterally or contralaterally to the IL-1beta injection site. Subcutaneous injection of IL-1beta produced mechanical allodynia and mirror-image mechanical allodynia in the orofacial area. Intracisternal administration of CPCCOEt, a mGluR1 antagonist, or MPEP, a mGluR5 antagonist, reduced IL-1beta-induced mechanical allodynia and mirror-image mechanical allodynia. Intracisternal administration of APDC, a group II mGluR agonist, or L-AP4, a group III mGluR agonist, reduced both IL-1beta-induced mechanical allodynia and mirror-image mechanical allodynia. The antiallodynic effect, induced by APDC or L-AP4, was blocked by intracisternal pretreatment with LY341495, a group II mGluR antagonist, or CPPG, a group III mGluR antagonist. These results suggest that groups I, II, and III mGluRs differentially modulated IL-1beta-induced mechanical allodynia, as well as mirror-image mechanical allodynia, in the orofacial area. PERSPECTIVE: Central group I mGluR antagonists and groups II and III mGluR agonists modulate IL-1beta-induced mechanical allodynia and mirror-image mechanical allodynia in the orofacial area. Therefore, the central application of group I mGluR antagonists or groups II and III mGluR agonists might be of therapeutic value in treating pain disorder. 相似文献
58.
稳定性核素测定大鼠小肠蛋白质合成 总被引:2,自引:1,他引:1
目的:建立稳定性核素([L-^15N]亮氨酸)测定大鼠小肠蛋白质合成率的方法。方法:分别测定静脉注射相同剂量[L-^15N]亮氨酸不同时相的大鼠小肠^15N丰度及不同剂量[L-^15N]亮氨酸同一时相的大鼠小肠^15N丰度。结果:大鼠小肠游离氨基酸池中^15N核素丰度在注射后0.5h内呈线性上升并达高峰,维持4h后缓慢下降,小肠蛋白质中的^15N丰度0.5h至12h基本维持不变;随着注射剂量的增加,大鼠小肠蛋白质分数合成率(FSR)亦增加,当[L-^15N]亮氨酸剂量在1.0mmol/kg以上,FSR并不随施加[L15N]亮氨酸剂量的加大而增加。结论:在进行大鼠小肠蛋白质合成率测定时,一次性静脉注射的测量最佳时限为0.5h,剂量为1.0mmol/kg。 相似文献
59.
60.
术后胆漏和继发胆管狭窄的内镜治疗 总被引:1,自引:1,他引:0
胆漏和继发胆管狭窄是严重的外科并发症,传统的治疗方法是再次开腹手术,但再手术并发症多,死亡率高。而内镜胆管造影不仅可明确诊断,且内镜下治疗具有安全、疗效肯定、创伤小和并发症少等优点,可作为大多数胆漏和胆管狭窄患者首选治疗方法。 相似文献